First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S. Falchook(HealthONE), David S. Hong(The University of Texas MD Anderson Cancer Center)
Cited by 88
Related Papers
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
|Nature Medicine|2023|185